RxDoctor Payments Data

Justin Saunders, MD

Clinical Cardiac Electrophysiology · Humble, TXNPI 1861602781

Payments from drug & device makers

$26,162in general payments, 2019–2025

Across 575 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$11K
  • Medtronic$5K
  • Boston Scientific$3K
  • Atricure, Inc.$1K
  • Cvrx, Inc.$832
  • Bard Peripheral Vascular, Inc.$724
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$5,88422%
  • Speaking & faculty fees$4,65018%
  • Travel & lodging$2,63210%
  • Food & beverage$12,96750%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,162 in reported general payments places this provider in the 40th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$283,401
Medicare patients
539
Services billed
3,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban417$473,795
XareltoRivaroxaban165$188,457
EntrestoSacubitril/Valsartan42$60,385
MultaqDronedarone Hcl26$47,199
Repatha SureclickEvolocumab25$17,107
Flecainide Acetate191$7,993
CorlanorIvabradine Hcl16$7,648
Amiodarone Hcl248$4,651
Metoprolol Succinate262$4,191
Dofetilide21$2,998
Valsartan29$2,010
SotalolSotalol Hcl92$1,801
Nebivolol Hcl23$1,429
Diltiazem 24hr ErDiltiazem Hcl19$1,234
ClopidogrelClopidogrel Bisulfate96$1,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$473,795417 claims
Johnson & JohnsonXarelto$159$188,457165 claims
NovartisEntresto$274$60,38542 claims
Sanofi-aventis U.S. LLCMultaq$245$47,19926 claims
AmgenCorlanor$246$7,64816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →